Coeptis Therapeutics (NASDAQ:COEP) Stock Price Down 5.7% – Should You Sell?

Shares of Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) dropped 5.7% during trading on Monday . The company traded as low as $15.75 and last traded at $16.51. Approximately 53,899 shares changed hands during trading, a decline of 9% from the average daily volume of 58,983 shares. The stock had previously closed at $17.50.

Coeptis Therapeutics Trading Down 5.7%

The company has a debt-to-equity ratio of 0.02, a current ratio of 0.83 and a quick ratio of 0.83. The business’s 50 day moving average is $12.86 and its 200 day moving average is $10.46. The stock has a market cap of $79.58 million, a price-to-earnings ratio of -2.85 and a beta of -0.57.

Coeptis Therapeutics (NASDAQ:COEP) last released its quarterly earnings data on Thursday, August 14th. The company reported ($1.17) earnings per share (EPS) for the quarter. The business had revenue of $0.20 million for the quarter.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.